Top Level Bribery And Medical Design Of Siemens

Recently, the Supreme People's court, the State Medical Insurance Bureau and the Central Commission for Discipline Inspection have successively issued documents to severely crack down on commercial bribery in the pharmaceutical field. Some people in the industry pointed out that at present, there are many information channels showing that the fight against commercial bribery in medicine will be promoted from the top-level design, information sharing, strengthening supervision and in-depth governance. As early as early as June, the National Health Commission and other nine departments issued a document emphasizing that by the end of 2020, the National Health Commission should take the lead and all member units should cooperate in accordance with the division of responsibilities to standardize the channels of medical business cooperation and communication.

Previously, a person in charge of the National Health Insurance Bureau said in an interview that according to the statistics of publicly available court judgments, more than half of China's top 100 pharmaceutical enterprises were found to have given or indirectly given kickbacks between 2016 and 2019. Among them, the most frequent enterprises have been involved in more than 20 cases in three years, and the rebate amount of a single case exceeds 20 million yuan. Not long ago, the people's Court of Chengdong District, Xining City, Qinghai Province, disclosed a criminal corruption case involving bribery by enterprises such as Philips and Siemens.

According to the reporter of 21st century economic report, many pharmaceutical enterprises are strengthening internal standardization, and some pharmaceutical enterprises are adjusting the positions of pharmaceutical representatives. "Commercial bribery exists in the purchase of medical consumables and drugs, but with the continuous promotion of procurement with quantity, the situation of commercial bribery will be less and less in the future, because there is no money to bribe." On September 22, Shi lichen, head of Beijing Dingchen medical management consulting center, said in an interview with 21st century economic reporter.

Bribery details exposed

Ge, Philips and Siemens, the multinational pharmaceutical giants known as "GPS", have almost monopolized China's medical equipment market. It is reported that the "three giants" have occupied more than 80% of the market share. However, in recent years, bribery scandals have frequently broken out in China's criminal cases.

Recently, in a criminal corruption case disclosed by the people's Court of Chengdong District, Xining City, Qinghai Province, Philips agents twice bribed Chai duo, then president of Xining first people's Hospital, with a total of more than 200000 yuan. Both times were due to the failure of the hospital to pay after the commissioning and installation of the color Doppler ultrasound machine. After accepting the bribe, Chai duo told the hospital to pay as soon as possible. In this case, Chai duo also helped Yang win the bid for Siemens dental chair, which was sold by Yang. Yang not only invited chaiduo to watch the air show in Zhuhai, but also gave chaiduo a fruit box containing 300000 yuan at Baiyun Airport.

In the case of Guo Jun, former party branch secretary and President of the first people's Hospital of Laishan District, Yantai City, Shandong Province, Philips color Doppler ultrasound equipment sales agents sold three Philips color Doppler ultrasound equipment to Laishan Branch hospital through Guo Jun. before and after, a total of 700000 "Commission" was paid to Guo Jun, and an additional 200000 yuan was given to Guo Jun, a total of 900000 yuan in cash was bribed to Guo Jun.

On July 30, according to Wang Jianmin's bribery crime document released by China judicial document website, Zhao of Zhiqing company sold Ge medical ultrasonic equipment to municipal hospital, and gave Wang, the middleman, about 210% promotion fee. Later, Wang used the promotion fee to Wang Jianmin, the then president of the municipal hospital, to purchase a house in Chengdu directly.

And Siemens is more generous in "product promotion". According to the U.S. Department of justice documents, from 2001 to 2007, Siemens Medical Group paid 14.4 million yuan to five Chinese hospitals. In 2015, Siemens' medical department was investigated by the State Administration for Industry and Commerce for suspected bribery of hospitals to use its high-priced medical products, involving as many as 1000 hospitals.

The "big action of bribery" of multinational pharmaceutical enterprises exposed the grey transaction between pharmaceutical agents and hospital leaders. However, from the current trial of corruption and bribery cases, the person in charge of hospitals is basically held responsible.

The above-mentioned cases are only the epitome of commercial bribery in the pharmaceutical industry. According to incomplete statistics, from 2010 to October 2019, there were 3113 bribery and bribery cases investigated in the pharmaceutical field, especially since 2013, with more than 3000 related cases. In addition to multinational pharmaceutical enterprises, there are many well-known pharmaceutical enterprises in China, such as Luo Mou, general manager of Sinopharm holding Qujing Co., Ltd., which ranks first in Qujing City The people's hospital received help in drug distribution, new drugs and antibiotic drug use. He bribed Zhang, the former president of the hospital for 12 times, totaling 1.13 million yuan.

Top design to attack medical bribery

Xiao Jiangping, director of the competition law research center of Peking University, pointed out that in the past, the prices of many drugs were unreasonably high, that is, some drugs were cheap, but after several links, they were very expensive in the hands of hospitals and patients, which was caused by commercial bribery.

In order to crack down on commercial bribery in the pharmaceutical industry, the relevant departments of the state have successively issued relevant policies and control measures, and many departments even jointly launched attacks.

For example, on September 17, the State Medical Insurance Bureau and the Supreme People's court jointly signed the memorandum of cooperation on information exchange and sharing of commercial bribery cases in the pharmaceutical field, which mainly includes the establishment of a regular notification system for commercial bribery cases in the pharmaceutical field, and the implementation of the enterprise credit information evaluation system established in the national centralized procurement, aiming to actively expand the Department of commercial bribery cases in the pharmaceutical field The application of the results of the method in the field of medical price and bidding and purchasing jointly promotes the reasonable return of medical price.

It is understood that the construction of enterprise credit information system in national centralized purchasing involves three aspects: one is to formulate the list of credit evaluation catalogue, and to include the behaviors of medical commercial bribery, monopoly behavior and improper price into the scope of medical price and bidding credit evaluation; the second is to establish a credit rating mechanism for pharmaceutical enterprises, and the provincial centralized purchasing agencies shall, in accordance with According to the judgment of the court or the administrative punishment decision, the credit rating of pharmaceutical enterprises in the local bidding procurement market is determined according to the nature, plot, time limit and influence of the dishonest behavior; the third is to establish a hierarchical disposal mechanism for dishonesty.

According to the credit rating of pharmaceutical enterprises, the provincial centralized purchasing agencies take measures such as warning in writing, reminding the purchasers of risk information relying on the centralized procurement platform, limiting or suspending the bidding of relevant drugs or medical consumables, and disclosing dishonest information to the public. When the circumstances are particularly serious, dishonest enterprises will face the risk of losing the centralized purchasing market.

In addition, on September 18, the website of the Central Commission for Discipline Inspection and supervision also published the article "discipline inspection and supervision organs strengthen the supervision in the medical field, focus on the risk points and cut off the interest chain" on September 18, which describes a number of cases of medical industry chaos rectification, and proposes that the discipline inspection and supervision organs should base on their functions and responsibilities, adhere to the problem orientation, comprehensively sort out the risk points and high risk mitigation in the medical field, and resolutely cut off the medical field In order to promote the medical industry to get rid of unhealthy tendencies and evils, we should focus on the interest chain of corruption.

A senior person in the pharmaceutical industry pointed out to the reporter of the 21st century economic report that after the Supreme People's court and the State Medical Insurance Bureau signed the memorandum of cooperation, such cases will surely be included in the enterprise credit evaluation of the medical insurance bureau, which may directly affect the work of purchasing with quantity.

Although the papers issued by several departments have a great deterrent effect on the industry, Shi lichen believes that the most crucial issue is the implementation of policies. For example, how many enterprises have entered the blacklist? Enterprises such as Buchang pharmaceutical and Hengrui pharmaceutical have the problem of commercial bribery, and more than once, have they been blacklisted? The price is the most important thing for Jicai. "

Moreover, Shi lichen also pointed out that the crackdown on the phenomenon of medical commercial bribery includes two aspects: legal level and non legal level. The legal level is the formulation of relevant laws and regulations. Non legal level is the issue of industry supervision. We should start from the supply side and hospitals, clarify and refine the responsibilities of pharmaceutical enterprises, agents, pharmaceutical representatives, hospital presidents, department directors and doctors, instead of simply and completely imputing the responsibility to enterprises.

According to Shi lichen, cracking down on commercial bribery in the pharmaceutical industry should not be the responsibility of one department, nor should each department act independently, but should be jointly operated by all departments to effectively crack down on it. In addition, it has gradually become a trend that medical consumables are included in the scope of centralized purchase with volume, and the profit space of drugs and medical consumables will be compressed. "With the continuous promotion of centralized purchasing, there will be less and less bribery in pharmaceutical business in the future, because by then, enterprises will have no money to bribe."

Wang Zhen, CEO of Bosia, believes that under the background of national centralized procurement and intensified anti-corruption efforts in medicine, pharmaceutical enterprises must face up to the internal compliance construction, and their marketing strategies will also be adjusted accordingly. "Under the superposition of multiple policies such as purchasing with quantity, tax verification and medical rectification, the traditional marketing mode of pharmaceutical enterprises is facing severe impact. Medical representatives on the front line also need to increase their awareness of compliance and safety. "